Hosted on MSN18d
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price TargetAn array of pharmaceutical pills with the company's logo on the bottle. Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments.
Barclays analyst Peter Lawson assigned a Buy rating to Relay Therapeutics (RLAY – Research Report) today and set a price target of $17.00. The company’s shares closed yesterday at $4.32.
Despite the competitive threat posed by Eli Lilly’s acquisition of Scorpion Therapeutics’ STX-478, which has shown promising efficacy in several cancer types, Relay Therapeutics’ RLY-2608 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback